Atorvastatin Calcium Hydrate/Dalcetrapib

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAtorvastatin Calcium Hydrate/Dalcetrapib
Drug Alias NameAtorvastatin/DalcetrapibAtorvastatin Calcium Hydrate and DalcetrapibDalcetrapib and Atorvastatin Calcium Hydrate
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsHDL-cholesterol stimulantsCholesteryl ester transfer protein inhibitors
TargetsHDL-cholesterolCholesteryl ester transfer proteinHMG-CoA reductase
Therapy Area/IndicationsLipid Metabolism Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes DalcetrapibAtorvastatin Calcium Hydrate
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsLipid Metabolism Disorders

Other Information

ATC CodeN/A
Related LinksN/A